Location: Hyderabad (Office)
Job Description Summary
#LI-Hybrid
Location: Hyderabad, India
Lead Global Transparency Solutions
Join Novartis and help shape the future of healthcare transparency. As a Lead in the Global Transparency Team (Ethics, Risk & Compliance), you'll drive global reporting compliance for regulations such as EFPIA, NPAG, US Sunshine, and local transparency requirements.
You'll lead a portfolio of strategic initiatives, driving system enhancements, regulatory change adoption, and data landscape transformations to ensure accurate, compliant, and efficient reporting worldwide.
This is a unique opportunity to combine compliance expertise, technology, and transformation leadership—translating complex regulations into scalable global solutions while leading a high-performing team in an agile environment.
Make an impact where ethics, technology, and global compliance come together.
The role has several responsibilities, including but limited to
- Regulatory Interpretation & Implementation
Interpret global transparency regulations (EFPIA, US Sunshine, and local laws) from a system and data perspective.
Translate regulatory changes, amendments, and industry codes (e.g., LDC, Control Room) into clear system and reporting requirements.
- Governance
Governance Documentation Management : Ensure all governance-related task position documents and Transparency Guidelines are reviewed bi-annually, kept up to date, and formally approved in collaboration with the respective Pillar Associate Director and GPO.
Knowledge Hub & Training Enablement : Maintain and regularly update Novartis Hub and training materials, ensuring accessibility, accuracy, and appropriate sign-offs from the Pillar Associate Director and GPO
- Global Systems & Data Landscape Enablement
Drive integration of regulatory requirements into global transparency platforms and solutions.
Lead system enhancements ensuring scalability, standardization, and alignment with enterprise architecture.
- Project & Portfolio Management
Manage a portfolio of regulatory and system transformation initiatives, ensuring alignment with ERC priorities.
Define delivery roadmaps, prioritization, and resource allocation across multiple concurrent projects.
- Acquisitions
- Lead the design and deployment of end-to-end transparency reporting processes for newly acquired entities, ensuring alignment with global standards and regulatory requirements.
- Define the operating model, roles, and ownership (Global, Country, Acquired Entity PoCs) for data collection, validation, and reporting.
- Establish transition frameworks to onboard acquired entities into Novartis Transparency systems and governance structures.
- Continuous Improvement & Risk Management
- Drive initiatives to simplify, harmonize, and standardize transparency reporting processes.
- Embed regulatory intelligence and forward-looking insights into planning and governance forums.
- Anticipate emerging regulatory trends and ensure future-ready system and process design.
Essential Requirements
08+ years (or equivalent) in pharmaceuticals or healthcare organisation.
Desirable Requirements
- Candidates should have 3+ years of experience in project coordination, operations, or stakeholder-facing roles.
- In-depth understanding of the Global Transparency Solutions is must.
- Proven experience in interpreting and applying global and local transparency regulations (e.g., EFPIA, US Sunshine Act) to reporting systems and processes.
- Strong skills in project planning, stakeholder management, communication, and problem-solving are essential.
- Hands-on involvement in the end-to-end lifecycle of regulatory report publication, including attestation, certification, and dispute resolution.
- Background in identifying and implementing system enhancements that improve data insights, reporting accuracy, and operational efficiency.
- Commitment To Diversity and Inclusion
Skills Desired
Business Acumen, Ethical Leadership, Prioritization, Risk Management, Self-Awareness, Stakeholder Management, Talent Development
Job description provided by Novartis.
View the original posting